Board of Directors
Denver Lough, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer, Chief Scientific Officer
Dr. Denver Lough has always sought to investigate reality, pursue complex simplicity and develop a new paradigm in translational science. He is the President, Chief Executive Officer and Chairman of PolarityTE, and discoverer of micro-aggregate cell-based technologies for applications in the regeneration of functionally-polarized tissues. A prior member of the Johns Hopkins Plastic and Reconstructive Surgery Program, Dr. Lough's interests surround pragmatic tissue engineering, deployable regenerative material constructs, real-time assessment of cell-to-tissue fate, reactivity, functionality and, ultimately, therapeutic efficacy in complex living systems. Dr. Lough has significant experience with bench-to-bedside translational applications from assays/equipment to IRB/clinical trial development to scientific writing and presenting. He is well-respected within the field by thought leaders, with numerous national awards and accolades, as well as the ability to access a wide variety of clinical and research networks and markets. Dr. Lough is experienced with IP and patent evolution, investment strategy, regulatory pathway systems, CLIA/ GLP manufacturing platforms, legal due diligence and business development. Dr. Lough holds an M.D. and PhD. in Biochemistry, Molecular and Cell Biology from Georgetown University and was a Senior Plastic Surgery Resident at Johns Hopkins before leaving his position to start PolarityTE.
Edward Swanson, M.D.
Executive Vice President, Chief Operating Officer & Director
Dr. Edward W. Swanson graduated with honors from the School of Engineering and Applied Sciences at the University of Pennsylvania, with a BAS in Applied Sciences in Biomedical Sciences in May 2007. His bioengineering background provided a framework of investigative thinking and a solutions oriented approach throughout the rest of his career focused on bridging the gap between translational and clinical medicine. He went on to graduate from Harvard Medical School, receiving an MD with Honors in May 2012. Throughout his training at UPenn and Harvard Medical School, he gained insight into a variety of fields at the basic science level and clinical research translation, including pancreatic cancer, traumatic brain injury, nanotechnology, tissue engineering, and vascularized composite allotransplantation. Following medical school, he joined the Plastic Surgery Residency Program at The Johns Hopkins University School of Medicine, where he focused on both the translational research approaches in regenerative medicine and vascularized composite allotransplantation, as well as patient outcomes within craniofacial surgery. His interests and goals remain focused on impacting patients’ lives clinically by translating innovative technology. Given the opportunity to develop the radical technological platform of PolarityTE into a clinical reality, Dr. Swanson elected to leave his plastic surgery career in December 2016.
Executive Vice President, Chief Financial Officer & Director
Since September 2015, John Stetson has served as Chief Financial Officer and Executive Vice President of the Company. Since 2010, he has been the Managing Member of HS Contrarian Investments LLC, a private investment firm with a focus on early stage companies. In addition, Mr. Stetson served as Executive Vice President, Chief Financial Officer, and Director of Marathon Patent Group, Inc. (MARA), a NASDAQ listed patenting company from June 2012 to February 2015. Mr. Stetson received his BA in Economics from the University of Pennsylvania.
Over the past 40 years, Mr. Gorlin has founded several biotechnology and pharmaceutical companies, including Hycor Biomedical, Inc. (acquired by Agilent), Theragenics Corporation, CytRx Corporation, Medicis Pharmaceutical Corporation (sold to Valeant for approximately $2.6 billion), EntreMed, Inc., MRI Interventions (MRIC), MiMedx, and Medivation, Inc. Mr. Gorlin has served on the Business Advisory Council to the Johns Hopkins School of Medicine and has previously served on The Johns Hopkins BioMedical Engineering Advisory Board. He also serves on the Board of the Andrews Institute. He founded a number of non-medical related companies, including Perma-Fix, Inc., Pretty Good Privacy, Inc. sold to Network Associates, Judicial Correction Services, Inc. sold to Correctional Healthcare, and NTC China. He started The Touch Foundation, a nonprofit organization for the blind and was a principal financial contributor to the founding of Camp Kudzu for diabetic children. He presently serves as the Vice Chairman of NantKwest, and serves on the Board of NTC China, Inc.
Jon Mogford, Ph.D
Dr. Jon Mogford, has served in various capacities for the Texas A&M University System (“Texas A&M”). Since May 2013, Dr. Mogford has served as the Vice Chancellor for Research, from August 2012 until April 2013 he served as the Chief Research Officer and from November 2011 until August 2012 he served as Associate Vice Chancellor for Strategic Initiatives at Texas A&M. Prior to joining the Texas A&M in 2011, from February 2010 until October 2011, Dr. Mogford served as Deputy Director of the Defense Sciences Office (DSO) of the Defense Advanced Research Projects Agency (DARPA) in the U.S. Department of Defense. From July 2005 until January 2009, Dr. Mogford served as Program Manager of DSO of DARPA. In addition, since November 2016, Dr. Mogford has served as a member of the board of directors of Medovex Corp. Dr. Mogford is the recipient of the Secretary of Defense Medal for Outstanding Public Service. Dr. Mogford obtained his bachelor’s degree in Zoology from Texas A&M University and doctorate in Medical Physiology from the Texas A&M University Health Science Center, College Station, Texas. His research in vascular physiology continued at the University of Chicago as a Postdoctoral fellow from 1997 until 1998. Dr. Mogford transitioned his research focus to the field of wound healing at Northwestern University, both as a Research Associate and also as a Research Assistant Professor from 1998 until 2003. He then served as a Life Sciences Consultant to DARPA on the Revolutionizing Prosthetics program from December 2003 until June 2005. Dr. Mogford is qualified to serve as a member of the Company’s Board because of his experience and research in regenerative medicine.
Jeff Dyer, MBA, PhD
Jeff Dyer (Ph.D UCLA) is the Horace Beesley professor of strategy at BYU as well as the Wharton School. Before becoming a professor, Dyer spent five years as a consultant and manager at Bain & Company. His Harvard Press books on innovation, The Innovator's DNA (with Clayton Christensen) and The Innovator's Method are business bestsellers and his research has been featured in publications such as Forbes, Economist, Fortune, BusinessWeek and the Wall Street Journal. Dyer is the only strategy scholar in the world to have published at least 6 times in both Harvard Business Reviewand Strategic Management Journal (the top academic journal in strategy). He was recently ranked #1 on a list of "most influential management scholars" based upon academic citations and Google searches to his name (among management scholars who received their Ph.D's after 1990). Dyer is co-founder of Innovator's DNA LLC, a fast growing innovation consultancy, and has consulted with such companies as Adobe, AT&T, Cisco, Gilead Sciences, Johnson and Johnson, Life Technologies, Magellan Health, Microsoft, NuVasive, and United Technologies.